September 2024

Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson & Johnso

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: